We're unable to sign you in at this time. Please try again in a few minutes.
We were able to sign you in, but your subscription(s) could not be found. Please try again in a few minutes.
There may be a problem with your account. Please contact the AMA Service Center to resolve this issue.
Contact the AMA Service Center:
Telephone: 1 (800) 262-2350 or 1 (312) 670-7827  *   Email: subscriptions@jamanetwork.com
Error Message ......
Observation |

Intralesional Rituximab for Primary Iris Lymphoma

Hakan Demirci, MD1; Joshua S. Grant, MD1; Victor M. Elner, MD, PhD1
[+] Author Affiliations
1Department of Ophthalmology and Visual Sciences, W. K. Kellogg Eye Center, University of Michigan, Ann Arbor
JAMA Ophthalmol. 2015;133(1):104-105. doi:10.1001/jamaophthalmol.2014.3303.
Text Size: A A A
Published online


Primary B-cell mucosa-associated lymphoid tissue (MALT) lymphoma of the iris is rare. The largest published series of 14 iris lymphomas included 3 such lymphomas.1 Thus, data concerning the effectiveness of treatment of these tumors are limited. External radiotherapy (the main treatment), resection, and systemic chemotherapy can cause substantial morbidity. Rituximab monoclonal antibody, targeting CD20 on B cells, has been used systemically and intralesionally to treat orbital and primary intraocular lymphomas and ocular inflammatory diseases.2,3 To our knowledge, we report the first case of primary iris MALT lymphoma treated with intralesional rituximab injection.

Figures in this Article

Sign in

Purchase Options

• Buy this article
• Subscribe to the journal
• Rent this article ?

First Page Preview

View Large
First page PDF preview


Place holder to copy figure label and caption
Iris Lymphoma of the Right Eye Before and After Therapy

A, Well-delineated, bilobed, vascularized, tan iris lesion. B, Anterior chamber angle involvement on gonioscopy. C, Ciliary body involvement on ultrasonographic biomicroscopy. D, Aspiration biopsy showing neoplastic medium-sized lymphocytes with hyperchromatic nuclei containing prominent nucleoli that contrast with small, reactive lymphocytes (hematoxylin-eosin, original magnification ×60). E, Numerous cells are CD20+ neoplastic B lymphocytes (immunohistochemistry, original magnification ×60). F, Few cells are reactive CD3+ T lymphocytes (immunohistochemistry, original magnification ×60). G, After 3 monthly intralesional rituximab injections, the tumor disappeared completely. H, The anterior chamber angle was free of tumor. I, No tumor was found on ultrasonographic biomicroscopy.

Graphic Jump Location




Also Meets CME requirements for:
Browse CME for all U.S. States
Accreditation Information
The American Medical Association is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The AMA designates this journal-based CME activity for a maximum of 1 AMA PRA Category 1 CreditTM per course. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Physicians who complete the CME course and score at least 80% correct on the quiz are eligible for AMA PRA Category 1 CreditTM.
Note: You must get at least of the answers correct to pass this quiz.
Please click the checkbox indicating that you have read the full article in order to submit your answers.
Your answers have been saved for later.
You have not filled in all the answers to complete this quiz
The following questions were not answered:
Sorry, you have unsuccessfully completed this CME quiz with a score of
The following questions were not answered correctly:
Commitment to Change (optional):
Indicate what change(s) you will implement in your practice, if any, based on this CME course.
Your quiz results:
The filled radio buttons indicate your responses. The preferred responses are highlighted
For CME Course: A Proposed Model for Initial Assessment and Management of Acute Heart Failure Syndromes
Indicate what changes(s) you will implement in your practice, if any, based on this CME course.


Some tools below are only available to our subscribers or users with an online account.

1 Citations

Sign in

Purchase Options

• Buy this article
• Subscribe to the journal
• Rent this article ?

Related Content

Customize your page view by dragging & repositioning the boxes below.

See Also...
Articles Related By Topic
Related Collections
PubMed Articles
Intralesional rituximab for primary iris lymphoma. JAMA Ophthalmol 2015;133(1):104-5.
An old disease in an atypical place. Surv Ophthalmol ;59(6):660-3.